ABION Presents ABN101 at US Chemical and Biological Defense Conference 'CBD S&T'... "Selected as the First Domestic Presenting Company"

Abion announced on the 18th that it will participate in the Chemical and Biological Defense Science & Technology Conference held in Florida, USA, from the 2nd to the 5th of next month.

Abion will conduct △an oral presentation on ABN101, an interferon-beta biobetter dry powder for the prevention and treatment of a wide range of respiratory viruses △a poster presentation on the efficacy and toxicity evaluation of ABN701, a vaccine targeting Staphylococcus aureus enterotoxin B △a poster presentation on ABN90X, a DNA (gene) vaccine delivery technology using microneedle patches and low-voltage electroporation. The company explained that this presentation is the first case among domestic companies and signifies that ABN101 is a leading technology in the global bio-defense market.

ABN101 is a therapeutic agent that suppresses virus replication through inhalation treatment in environments such as biochemical weapon dispersal or chemical and biological warfare. When its antiviral efficacy was announced at the TechWatch Forum in the US last June, it attracted significant interest from the US Department of Defense and bio companies, leading to its selection as an oral presentation topic at this conference. New research results applying the microneedle formulation to hepatitis viruses and others will also be disclosed at this presentation.

ABN701, which has demonstrated excellent immunogenicity, efficacy, and safety in various animal models, is a vaccine targeting Staphylococcus aureus enterotoxin B, which causes acute gastrointestinal symptoms such as vomiting and diarrhea. ABN90X is a project developing vaccines, antisera, antibodies, and gene therapies for infectious disease response.

A company official stated, “This will be a meaningful opportunity to share the achievements of Abion’s accumulated vaccines and therapeutics, especially ABN101, which has high demand in bio-defense technology,” adding, “This conference is an optimal venue to seek research collaboration and business development (BD) partnering in the field of chemical and biological defense.” He emphasized, “We plan to actively engage in cooperation discussions with US Department of Defense agencies and global pharmaceutical companies.”